Company / Cost of Revenue
Neurocrine Biosciences Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$52.1M
FY2025
5-year range
$14.3M / $52.1M
FY2021-FY2025
Trend
+53.2%
vs FY2024
Sector context
#53 of 83
Health Care
What the data says
At $52M, Neurocrine Biosciences's cost of revenue ranks #31 of 83 in the Health Care sector. Increased from $40M to $52M over the past 2 years.
Based on SEC 10-K filings.
$52M in FY2025 with a 5-year CAGR of +38.8%.
Increased from $40M to $52M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +31.0%
- 5-Year CAGR
- +38.8%
- 10-Year CAGR
- -
Sector benchmark
#31 of 83 in Health CareTop 36% of 83This company $52.1M Sector average $2.0B
▼
-97.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +38.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 53.2% year-over-year.
- Ranks #53 out of 83 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.1M | +53.2% |
| FY2024 | $34.0M | -14.4% |
| FY2023 | $39.7M | +71.1% |
| FY2022 | $23.2M | +62.2% |
| FY2021 | $14.3M | +41.6% |
| FY2020 | $10.1M | - |
| FY2019 | - | - |
| FY2018 | $4.9M | +289.9% |
| FY2017 | $1.3M | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026